Heather Wilkins

The paper benchmarks proteomic biomarkers and drug targets in patient-derived cerebral organoids against clinical cohorts, finding they detect most candidates and replicate disease changes in a quarter of reproducible markers.

This study shows that estrogen therapy restores synaptic and metabolic proteins in the brain of aged mice after ovariectomy, improving mitochondrial function and synaptic integrity.

In 4-month-old APOE targeted-replacement mice, APOE4 remodels the liver proteome sex-dependently; in isogenic iPSC-derived hepatocytes it impairs respiration and raises glycolysis and lipid droplets.

This study shows that AHA1 regulates Aβ production by modulating APP expression and γ-secretase assembly, suggesting it as a therapeutic target for Alzheimer's disease.

This study identifies APOE4-dependent metabolic changes in brain cells, showing increased glycolysis and mitochondrial dysfunction in neurons and astrocytes.

This study identifies an APOE4-specific cerebrospinal fluid proteome signature using machine learning, independent of Alzheimer's disease diagnosis and associated with increased risk of cognitive impairment.